Fred Hutch News ServiceFirst systematic study of infections after CAR T-cell therapyFred Hutch News Service“Understanding the impact of infectious complications of CD19 CAR T-cell immunotherapy is an important goal that will help us design safer ways t… Continue reading
Fred Hutch News ServiceFirst systematic study of infections after CAR T-cell therapyFred Hutch News Service“Understanding the impact of infectious complications of CD19 CAR T-cell immunotherapy is an important goal that will help us design safer ways t… Continue reading
Cancer Immunotherapy Market Is Projected To Register A Robust CAGR In Future | Radiant Insights,IncDigital JournalAccording to the findings of a report made available by Radiant Insights, Inc., the global cancer immunotherapy market is projected to reg… Continue reading
|
Missouri S&T students clean up water through plant biology
Missouri S&T News and Research “A major slowdown in synthetic biology research is redesigning every single DNA part for every individual project,” says Erin Nischwitz, S&T’s iGEM team leader. “iGEM teams around the world create parts of DNA that will act the same way in multiple … |
Life Sciences Intellectual Property Review |
FDA OKs Nationwide Children’s Hospital’s IND for Sarepta’s microdystrophin gene therapy for DMD; shares up 2%
Seeking Alpha The FDA has signed off on Nationwide Children’s Hospital’s IND application seeking approval to begin a Phase 1/2a study of evaluating a new gene therapy candidate, AAVrh74.MHCK7.micro-Dystrophin, in patients with Duchenne muscular dystrophy (DMD) … Sarepta Therapeutics (SRPT): FDA Clears GALGT2 Gene Therapy Program – William BlairStreetInsider.com Sarepta Therapeutics and Nationwide Children’s Hospital Announce FDA Clearance of IND for Micro-Dystrophin Gene …GlobeNewswire (press release) Sarepta Therapeutics And Nationwide Children’s Hospital Announce US Food And Drug Administration (FDA …Clinical Leader |